It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mechanosensitive PIEZO2 ion channels play roles in touch, proprioception, and inflammatory pain. Currently, there are no small molecule inhibitors that selectively inhibit PIEZO2 over PIEZO1. The TMEM120A protein was shown to inhibit PIEZO2 while leaving PIEZO1 unaffected. Here we find that TMEM120A expression elevates cellular levels of phosphatidic acid and lysophosphatidic acid (LPA), aligning with its structural resemblance to lipid-modifying enzymes. Intracellular application of phosphatidic acid or LPA inhibits PIEZO2 but not PIEZO1 activity. Extended extracellular exposure to the non-hydrolyzable phosphatidic acid and LPA analog carbocyclic phosphatidic acid (ccPA) also inhibits PIEZO2. Optogenetic activation of phospholipase D (PLD), a signaling enzyme that generates phosphatidic acid, inhibits PIEZO2 but not PIEZO1. Conversely, inhibiting PLD leads to increased PIEZO2 activity and increased mechanical sensitivity in mice in behavioral experiments. These findings unveil lipid regulators that selectively target PIEZO2 over PIEZO1, and identify the PLD pathway as a regulator of PIEZO2 activity.
Mechanosensitive channel PIEZO2, but not PIEZO1, can be inhibited by the protein TMEM120A (TACAN), but the mechanism was unclear. Here, the authors show that TMEM120A increases the levels of phosphatidic acid, which is shown to be a selective inhibitor of PIEZO2.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Rutgers University New Jersey Medical School, Department of Pharmacology, Physiology & Neuroscience, Newark, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)
2 Rutgers Cancer Institute of New Jersey, Metabolomics Shared Resource, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 0405 0718); Tsinghua University, School of Pharmaceutical Sciences, Tsinghua—Peking Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, Beijing, China (GRID:grid.12527.33) (ISNI:0000 0001 0662 3178)
3 Rutgers Cancer Institute of New Jersey, Metabolomics Shared Resource, New Brunswick, USA (GRID:grid.12527.33) (ISNI:0000 0004 0405 0718)